IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

:

Kazuo SUZUKI et al.

Mail Stop: PCT

Serial No. NEW

Attorney Docket No. 2006 1634A

Filed September 26, 2006

INSULIN RESISTANCE-IMPROVING AGENT [Corresponding to PCT/JP2005/005472 Filed March 25, 2005]

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

	[X]	each U.S. Patent and U.S. Patent application publication;					
	0	each reference previously cited in the international application PCT/; and/or					
	O	each reference previously cited in prior parent application Serial No.					
la.	[X] Thi	[X] This Information Disclosure Statement is submitted:					
	within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or						
	before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,						

and thus no certification and/or fee is required.

1b. [] This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

- (1) [] the certification of paragraph 2 below is provided, or
- (2) [] the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.
- 1c. [] This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

- 2. It is hereby certified
 - a. [] that each item of information contained in this Information Disclosure

 Statement was first cited in any communication from a foreign patent office in a

 counterpart foreign application not more than three months prior to the filing of
 the Statement, or
 - b. [] that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.
- [X] Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.
 Serial No. 10/485,217

IAP16 Rec'd PCT/PTO 26 SEP 2006 10/594215

4.	For each non-English language reference listed on the attached form PTO-1449, reference is made to:						
	a. []	a full or partial English language translation submitted herewith,					
	b. []	a foreign patent office search report (in the English language) submitted herewith,					
	c. []	the concise explanation contained in the specification of the present application at page,					
	d. []	the concise explanation set forth in the attached English language abstract,					
	e. []	the concise explanation set forth below or on a separate sheet attached to the reference:					

Respectfully submitted,

[X] A foreign patent office search report citing one or more of the references is enclosed.

Kazuo SUZUKI et al.

By Warren M. Cheek, Ir. Registration No. 33,367 Attorney for Applicants

WMC/dlk Washington, D.C. 20006-1021 Telephone (202) 721-8200 Facsimile (202) 721-8250 September 26, 2006

5.

Sheet 1 of 1			INFORMA	TION DISCLO	SURE STATEMENT	ec a roll	10 265	EP 2000	
FORM PTO 1449 (r	TMENT OF COMMERCIA	ATTY DOCKET NO. SERIAL NEW		N° 10/594215					
PATENT AND TRADEMARK OFFICE				APPLICANT Kazuo SUZUKI et al.					
	LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Date Submitted to PTO: September 26, 2006						GROUP		
				September 26, 2006 S. PATENT DOCUMENTS					
*EXAMINER INITIAL			DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	AA	5,298,497	3/1994	Tsch	ollar et al.				
	AB	2004/0191209	9/2004		Oba			Corresponds to AJ	
	AC								
	AD								
	AE								
	AF								
	AG								
	АН								
	AI								
			FORE	IGN PATENT	DOCUMENTS				
		DOCUMENT NUMBER	DATE	co	OUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	AJ	03/011308	2/2003		wo			Abstract	
	AK	2002-537390	11/2002		JP				
	AL	00/50414	8/2000		wo			Corresponds to AK	
	AM	2003-055235	2/2003		JP			Abstract	
	AN								
····		OTHER	DOCUMENT(S) (I	ncluding Autho	r, Title, Date, Pertin	ent Pages, Etc.)			
	AO A. Garg et al., "Cholestyramine Therapy for Dyslipidemia in Non-Insulin-Dependent Diabetes Mellitus", Ann Intern Med., Vol. 121, pp. 416-422, 1994.								
	AP								
	AQ								
EXAMINER			DATE CONSIDERED						